Search

Displaying results 2281 - 2290 of 10000 in total
  1. Drug

    Amylmetacresol

    go.drugbank.com/drugs/DB13908
    Approved

    Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the treatment of sore throat and minor mouth infections [L2570], [L2571]. … The acute sore throat (pharyngitis) is one of the most common conditions for which children are seen in the primary care setting.

    Synonyms: 6-n-amyl-m-cresol, 6-n-pentyl-m-cresol
  2. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.

  3. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors. … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement

  4. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … difficulties and commercial infeasibility in continuing drug distribution.

  5. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse … [A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants.

  6. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.

  7. Drug

    Albutrepenonacog alfa

    go.drugbank.com/drugs/DB13884
    Approved

    [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016. … It is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305]

  8. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]

  9. Drug

    Cabergoline

    go.drugbank.com/drugs/DB00248
    ApprovedInvestigational

    Cabergoline possesses potent agonist activity on dopamine D2 receptors. … Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome.

    Synonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
  10. Drug

    Latamoxef

    go.drugbank.com/drugs/DB04570
    Approved

    Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins